Bookmark

Add to MyYahoo RSS

Pharmacyclics News

News on Pharmacyclics (Ticker: PCYC) continually updated from thousands of sources around the net.

Yesterday | Medical News

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA in the European Union.

Comment?

Related Topix: Startups, Marketing, Leukemia, Health, Food and Drug Administration, Medicine

Thu Jul 24, 2014

Drug Researcher

Profits and capacity utilisation up at Lonza in H1 thanks to pharma

Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.

Comment?

Related Topix: Medicine, Health, Breast Cancer, Startups

EurekAlert!

Biomedical engineer looks at new applications for novel lupus drug

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases.

Comment?

Related Topix: Medicine, Lupus, University of Houston, Startups

Wed Jul 23, 2014

The Motley Fool

Is Gilead About to Crush Pharmacyclics Stock?

However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will regulate Imbruvica to the back-burner in chronic lymphocytic leukemia, or CLL, they should recognize that Imbruvica may do very well on its own despite the threat.

Comment?

Related Topix: Startups, Leukemia, Health, Healthcare Law, Law

Theflyonthewall.com

Pharmacyclics estimates raised ahead of Q2 report at Goldman

Pharmacyclics estimates raised ahead of Q2 report at Goldman Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data.

Comment?

Related Topix: Startups

Mon Jun 30, 2014

AmericanBankingNews.com

Pharmacyclics Receives Outperform Rating from Credit Suisse

's stock had its "outperform" rating restated by analysts at Credit Suisse in a research report issued to clients and investors on Monday.

Comment?

Related Topix: Startups

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••